Other News

BioSig Announces Pricing of Public Offering of Common Stock

Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced […]

Philips announces first patient treated with its new real-time 3D intracardiac echocardiography catheter – VeriSight Pro

July 01, 2021 FDA 510k-cleared real-time 3D intracardiac echocardiography (ICE) catheter has potential to improve standard of care for structural heart disease and electrophysiology procedures Reduced need for general anesthesia accelerates workflows, increases efficiency, and broadens treatment options Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in […]

DiNAQOR Expands Board of Directors with Three Renowned Cardiovascular Industry and Academic Experts

PFÄFFIKON, Switzerland, July 1, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced that it has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D. “We are extremely proud to welcome […]

Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel

WARRINGTON, Pa., July 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Diane Carman, Esq. as Senior Vice President and General Counsel, reporting to Craig Fraser, President and Chief Executive Officer. Ms. Carman […]

Hoag Begins Enrolling Patients with Degenerative Mitral Valve Disease in Clinical Trial Using a Less Invasive Surgical Treatment

The RESTORE trial will test the safety and efficacy of the HARPOON™ Beating Heart Mitral Valve Repair System. New minimally invasive device could reduce pain, complications and recovery time for mitral valve repair surgery. Hoag is one of only 40 sites in the world selected for this trial. NEWPORT BEACH, […]

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes London, UK, 1 July 2021 – George Medicines, a late-stage drug development company focused […]

Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)

REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsi Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per month versus baseline Clinically important improvement in quality of life maintained even up to 12 months post-implantation Safety profile remains in line […]

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently in an ongoing global Phase 2b clinical trial in patients […]

Cardior Appoints Dr. Rahul Agrawal as Chief Medical Officer

HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiac diseases, today announced the appointment of Rahul Agrawal, MD, as Chief Medical Officer. Dr. Agrawal brings more than 20 years of industry experience from global and senior medical […]